Transcription factor 7-like 2 (TCF7L2) polymorphism and context-specific risk of impaired fasting glucose in African American and Caucasian adults: The atherosclerosis risk in communities (ARIC) study

Diabetes/Metabolism Research and Reviews

Volumn 26, Issue 5, 2010, Pages 371-377

  Yan, Yu ^a   North, Kari E ^a,b   Heiss, Gerardo ^a   Klein, Ronald ^c   Girman, Cynthia J ^a,d   Lange, Ethan M ^e   Pankow, James S ^f   Brancati, Frederick L ^g,h   Boerwinkle, Eric ⁱ  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF TEXAS   (United States)

Author keywords

Gene environment interaction; Impaired fasting glucose; Transcription factor 7 like 2 (TCF7L2)

Indexed keywords

GLUCOSE; TRANSCRIPTION FACTOR 7 LIKE 2; TRIACYLGLYCEROL; T CELL FACTOR PROTEIN; TCF7L2 TRANSCRIPTION FACTOR;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISORDERS OF CARBOHYDRATE METABOLISM; FEMALE; FOLLOW UP; FOOD INTAKE; GENE INTERACTION; GLUCOSE BLOOD LEVEL; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IMPAIRED FASTING GLUCOSE; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; ATHEROSCLEROSIS; BLOOD; DIET RESTRICTION; GENE FREQUENCY; GENETICS; GLUCOSE INTOLERANCE; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; METABOLISM; MIDDLE AGED; RISK;

AFRICAN AMERICANS; ATHEROSCLEROSIS; BLOOD GLUCOSE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FASTING; FEMALE; GENE FREQUENCY; GLUCOSE INTOLERANCE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; OBESITY; PREDIABETIC STATE; RISK; TCF TRANSCRIPTION FACTORS;

EID: 77954173414     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1087     Document Type: Article

References (32)

1. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30(3): 753-759. (Pubitemid 46354366)
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007; 30(Suppl 1): S42-S47.
3. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38(3): 320-323.
4. Cauchi S, El Achhab Y, Choquet H, et al. TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis. J Mol Med 2007; 85(7): 777-782.
5. Florez JC, Jablonski KA, Bayley N, et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006; 355(3): 241-250.
6. Melzer D, Murray A, Hurst A, et al. Effects of the diabetes linked TCF7L2 polymorphism in a representative older population. BMC Medicine 2006; 4(1): 34.
7. Raitakari OT, Ronnemaa T, Huupponen R, et al. The Cardiovascular Risk in Young Finns Study. Variation of the transcription factor 7-like 2 (TCF7L2) gene predicts impaired fasting glucose in healthy young adults. Diabetes Care 2007; 30(9): 2299-2301.
8. Yan Y, North KE, Ballantyne CM, et al. The Atherosclerosis Risk in Communities Study. Transcription factor 7-like 2 (TCF7L2) polymorphism and context-specific risk of type 2 diabetes in African American and Caucasian adults. Diabetes 2009; 58(1): 285-289.
9. Helgason A, Palsson S, Thorleifsson G, et al. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 2007; 39(2): 218-225.
10. Cauchi S, Froguel P. TCF7L2 genetic defect and type 2 diabetes. Curr Diab Rep 2008; 8(2): 149-155.
11. The ARIC Investigators. The Atherosclerosis Risk in Communnities (ARIC) Study: design and objectives. Am J Epidemiol 1989; 129(4): 687-702.
12. US Department of Health and Human Service. The Practical Guide - Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH publication no. 004084. National Institutes of Health: Bethesda, MD, 2000.
13. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement: Executive Summary. Circulation 2005; 112(17): e285-e290.
14. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6): 1206-1252.
15. Eckfeldt JH, Chambless LE, Shen YL. Short-term, within-person variability in clinical chemistry test results. Experience from the Atherosclerosis Risk in Communities Study. Arch Pathol Lab Med 1994; 118(5): 496-500.
16. Expert Panel on Detection EaToHBCiA. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-2497.
17. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J ClinNutr 1982; 36(5): 936-942.
18. Pencina MJ, Larson MG, D'Agostino RB. Choice of time scale and its effect on significance of predictors in longitudinal studies. Stat Med 2007; 26(6): 1343-1359.
19. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989; 129(1): 125-137. (Pubitemid 19030705)
20. Rothman KJ, Greenland S. Modern Epidemiology (2nd edn). Lippincott-Raven: Philadelphia, PA, 1998.
21. Li R, Chambless L. Test for additive interaction in proportional hazards models. Ann Epidemiol 2007; 17(3): 227-236. (Pubitemid 46298822)
22. Greenland S. Tests for interaction in epidemiologic studies: a review and a study of power. Stat Med 1983; 2(2): 243-251. (Pubitemid 13020136)
23. Gauderman W, Morrison J. QUANTO 1.1: A Computer Program for Power and Sample Size Calculations for Genetic-epidemiology Studies. 2006; http://hydra.usc.edu/gxe, Accessed in 2009.
24. Richardson MT, Ainsworth BE, Wu HC, et al. Ability of the Atherosclerosis Risk in Communities (ARIC)/Baecke Questionnaire to assess leisure-time physical activity. Int J Epidemiol 1995; 24(4): 685-693.
25. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 2000; 19(9): 1141-1164. (Pubitemid 30265928)
26. Munoz J, Lok KH, Gower BA, et al. Polymorphism in the transcription factor 7-like 2 (TCF7L2) gene is associated with reduced insulin secretion in nondiabetic women. Diabetes 2006; 55(12): 3630-3634.
27. Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007; 117(8): 2155-2163.
28. Loos RJ, Franks PW, Francis RW, et al. TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population. Diabetes 2007; 56(7): 1943-1947.
29. Humphries SE, Gable D, Cooper JA, et al. Common variants in the TCF7L2 gene and predisposition to type 2 diabetes in UK European Whites, Indian Asians and Afro-Caribbean men and women. J MolMed 2006; 84(12): 1-10.
30. Horikoshi M, Hara K, Ito C, et al. A genetic variation of the transcription factor 7-like 2 gene is associated with risk of type 2 diabetes in the Japanese population. Diabetologia 2007; 50(4): 747-751. (Pubitemid 46355825)
31. Li JK, Ng MC, So WY, et al. Phenotypic and genetic clustering of diabetes and metabolic syndrome in Chinese families with type 2 diabetes mellitus. Diabetes Metab Res Rev 2006; 22(1): 46-52.
32. Shaw JT, Purdie DM, Neil HA, et al. The relative risks of hyperglycaemia, obesity and dyslipidaemia in the relatives of patients with Type II diabetes mellitus. Diabetologia 1999; 42(1): 24-27.